83 research outputs found
Effect of the melanocortin-3 receptor C17A and G241A variants on weight loss in childhood obesity
n/
Age-related impairment in insulin release: the essential role of ϐ(2)-adrenergic receptor.
In this study, we investigated the significance of ϐ (2)-adrenergic receptor (ϐ (2)AR) in age-related impaired insulin secretion and glucose homeostasis. We characterized the metabolic phenotype of ϐ (2)AR-null C57Bl/6N mice (ϐ (2)AR(-/-)) by performing in vivo and ex vivo experiments. In vitro assays in cultured INS-1E ϐ-cells were carried out in order to clarify the mechanism by which ϐ (2)AR deficiency affects glucose metabolism. Adult ϐ (2)AR(-/-) mice featured glucose intolerance, and pancreatic islets isolated from these animals displayed impaired glucose-induced insulin release, accompanied by reduced expression of peroxisome proliferator-activated receptor (PPAR) γ, pancreatic duodenal homeobox-1 (PDX-1), and GLUT2. Adenovirus-mediated gene transfer of human ϐ (2)AR rescued these defects. Consistent effects were evoked in vitro both upon ϐ (2)AR knockdown and pharmacologic treatment. Interestingly, with aging, wild-type (ϐ (2)AR(+/+)) littermates developed impaired insulin secretion and glucose tolerance. Moreover, islets from 20-month-old ϐ (2)AR(+/+) mice exhibited reduced density of ϐ (2)AR compared with those from younger animals, paralleled by decreased levels of PPARγ, PDX-1, and GLUT2. Overexpression of ϐ (2)AR in aged mice rescued glucose intolerance and insulin release both in vivo and ex vivo, restoring PPARγ/PDX-1/GLUT2 levels. Our data indicate that reduced ϐ (2)AR expression contributes to the age-related decline of glucose tolerance in mice
Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit
Integrins are heterodimeric receptors that play a critical role in cell-cell and cell-matrix adhesion processes. Among them, αVβ3 integrin, that recognizes the aminoacidic RGD triad, is reported to be involved in angiogenesis, tissue repair and tumor growth. We have recently synthesized a new and selective ligand of αVβ3 receptor, referred to as RGDechiHCit, that contains a cyclic RGD motif and two echistatin moieties.The aim of this study is to evaluate in vitro and in vivo the effects of RGDechiHCit. Therefore, we assessed its properties in cellular (endothelial cells [EC], and vascular smooth muscle cells [VSMC]) and animal models (Wistar Kyoto rats and c57Bl/6 mice) of angiogenesis.In EC, but not VSMC, RGDechiHCit inhibits intracellular mitogenic signaling and cell proliferation. Furthermore, RGDechiHCit blocks the ability of EC to form tubes on Matrigel. In vivo, wound healing is delayed in presence of RGDechiHCit. Similarly, Matrigel plugs demonstrate an antiangiogenic effect of RGDechiHCit.Our data indicate the importance of RGDechiHCit in the selective inhibition of endothelial αVβ3 integrin in vitro and in vivo. Such inhibition opens new fields of investigation on the mechanisms of angiogenesis, offering clinical implications for treatment of pathophysiological conditions such as cancer, proliferative retinopathy and inflammatory disease
Targeting the CaMKII/ERK Interaction in the Heart Prevents Cardiac Hypertrophy
AIMS: Activation of Ca2+/Calmodulin protein kinase II (CaMKII) is an important step in signaling of cardiac hypertrophy. The molecular mechanisms by which CaMKII integrates with other pathways in the heart are incompletely understood. We hypothesize that CaMKII association with extracellular regulated kinase (ERK), promotes cardiac hypertrophy through ERK nuclear localization. METHODS AND RESULTS: In H9C2 cardiomyoblasts, the selective CaMKII peptide inhibitor AntCaNtide, its penetratin conjugated minimal inhibitory sequence analog tat-CN17β, and the MEK/ERK inhibitor UO126 all reduce phenylephrine (PE)-mediated ERK and CaMKII activation and their interaction. Moreover, AntCaNtide or tat-CN17β pretreatment prevented PE induced CaMKII and ERK nuclear accumulation in H9C2s and reduced the hypertrophy responses. To determine the role of CaMKII in cardiac hypertrophy in vivo, spontaneously hypertensive rats were subjected to intramyocardial injections of AntCaNtide or tat-CN17β. Left ventricular hypertrophy was evaluated weekly for 3 weeks by cardiac ultrasounds. We observed that the treatment with CaMKII inhibitors induced similar but significant reduction of cardiac size, left ventricular mass, and thickness of cardiac wall. The treatment with CaMKII inhibitors caused a significant reduction of CaMKII and ERK phosphorylation levels and their nuclear localization in the heart. CONCLUSION: These results indicate that CaMKII and ERK interact to promote activation in hypertrophy; the inhibition of CaMKII-ERK interaction offers a novel therapeutic approach to limit cardiac hypertrophy
An approach to prevent frailty in community dwelling older adults: a pilot study performed in Campania region in the framework of the PERSSILAA project
We developed and tested an innovative physical
training method in older adults that embeds the gym
program into everyday life in the most conservative
way possible. Physical training was included in the
activities of local parishes where older women from
Southern Italy spend most of their free time and was
delivered by trained physical therapists with the
support of an ICT tool known as CoCo. 113 older
women (aged 72.0 [69.0-75.0] years) noncompliant
to conventional exercise programs participated to
the study. 57 of them underwent the final
anthropometric assessment and 50 the final physical
tests. In study completers handgrip strength and
physical performance evaluated with the chair-stand,
the two minutes step and the chair-sit and -reach
tests significantly improved. Quality of life as
evaluated with the EuroQol-5dimension (EQ-5D)
questionnaire improved as well. In conclusion, a
training program designed to minimally impact on
life habits of older people is effective in improving
fitness in patients noncompliant to other to physical
exercise programs
The Association of PNPLA3 Variants with Liver Enzymes in Childhood Obesity Is Driven by the Interaction with Abdominal Fat
BACKGROUND AND AIMS: A polymorphism in adiponutrin/patatin-like phospholipase-3 gene (PNPLA3), rs738409 C->G, encoding for the I148M variant, is the strongest genetic determinant of liver fat and ALT levels in adulthood and childhood obesity. Aims of this study were i) to analyse in a large group of obese children the role of the interaction of not-genetic factors such as BMI, waist circumference (W/Hr) and insulin resistance (HOMA-IR) in exposing the association between the I148M polymorphism and ALT levels and ii) to stratify the individual risk of these children to have liver injury on the basis of this gene-environment interaction. METHODS: 1048 Italian obese children were investigated. Anthropometric, clinical and metabolic data were collected and the PNPLA3 I148M variant genotyped. RESULTS: Children carrying the 148M allele showed higher ALT and AST levels (p = 0.000006 and p = 0.0002, respectively). Relationships between BMI-SDS, HOMA-IR and W/Hr with ALT were analysed in function of the different PNPLA3 genotypes. Children 148M homozygous showed a stronger correlation between ALT and W/Hr than those carrying the other genotypes (p: 0.0045) and, therefore, 148M homozygotes with high extent of abdominal fat (W/Hr above 0.62) had the highest OR (4.9, 95% C. I. 3.2-7.8, p = 0.00001) to develop pathologic ALT. CONCLUSIONS: We have i) showed for the first time that the magnitude of the association of PNPLA3 with liver enzymes is driven by the size of abdominal fat and ii) stratified the individual risk to develop liver damage on the basis of the interaction between the PNPLA3 genotype and abdominal fat
Innovative approaches to active and healthy ageing: Campania experience to improve the adoption of innovative good practices
The demographic projections on the
European population predict that people aged over
60 will increase by about two million/year in the next
decades. Since 2012, the Campania Reference Site of
the European Innovation Partnership on Active and
Healthy Ageing supports the innovation of the
Regional Health System, to face up demographic
changes and sustainability. Campania Reference Site
provides the opportunity to connect loco-regional
stakeholders in social and health care services
(universities, healthcare providers, social services,
local communities and municipalities), with
international organizations, in order to adopt and
scale up innovative solutions and approaches. This
paper describes the building process of Campania
Reference Site and the main results achieved, that
have been allowing it to become a hub for open
innovation in the field of active and healthy aging at
regional, national and international level
SM13 regola l'interazione MDM2 – P53: effetti sul cancro e sul danno vascolare
Background: p53 è un noto soppressore tumorale che agisce regolando l'apoptosi in risposta al danno cellulare, regolando diversi meccanismi all'interno della cellula, come l'arresto del ciclo cellulare e l'apoptosi mitocondriale indipendentemente dalla sua attività trascrizionale. Recentemente sono stati sintetizzati due nuovi composti (ISA27 e SM13), che bloccano l'interazione MDM2-p53 e sono in grado di indurre apoptosi in cellule tumorali p53 wild-type (wt). Inoltre è noto che p53 è attivo nelle lesioni iperplastiche vascolari, nelle quali induce l'apoptosi delle cellule muscolari lisce (VSMC). Lo scopo di questo studio è stato quello di verificare l'efficacia di questi composti in tumori generati da una forma mutata del gene p53 senza attività trascrizionale (p53mt), e se p53 possa essere un target terapeutico per il trattamento di malattie vascolari, alla base delle quali vi è una iperproliferazione delle cellule vascolari
lisce.
Metodi: in vitro è stata valutata l'efficacia dei peptidi in linee cellulari tumorali con il gene p53wt, p53 mutato (p53mt) e p53 knock out (p53ko), e nella linea cellulare
VSMC. Lo studio in vivo è stato eseguito in topi nudi Balb/c.
Risultati: Sia ISA27 che SM13 riducono la proliferazione cellulare ed inducono apoptosi in vitro in cellule p53wt e p53mt, suggerendo che il meccanismo d'azione è p53 dipendente, non avendo alcun effetto nella linea tumorale p53ko, ma è indipendente dall'attività trascrizionale di p53. In vivo, ISA27 e SM13 inducono morte cellulare in
maniera dose dipendente attraverso l'attivazione della via apoptotica mitocondriale. In partiolare SM13 è più efficace di ISA27 nel ridurre la crescita del tumore. Nelle VSMC, il trattamento con SM13 è risultato efficace nel ridurre l'interazione p53/MDM2 ed aumentare i livelli di p53. Inoltre, in queste cellule SM13 inibisce la proliferazione cellulare e la sintesi del DNA ed è in grado in vitro, di indurre apoptosi p53 – dipendente.
Conclusione: Il nostro studio propone SM13 come composto anti-tumorale da utilizzare per il trattamento di tumori p53 dipendenti, anche in assenza di attività trascrizionale p53, e dimostra l'efficacia di SM13 nel ridurre la proliferazione delle VSMC, attraverso l'attivazione di un pathway apoptotico p53-dipendente, suggerendo il suo impiego in malattie vascolari iperproliferative, quali aterosclerosi e restenosi
Ovarian refractoriness to gonadotropins and evaluation of estrogen-prolactin feedback in hyperprolactinemic states: experimental studies
[Effect of oral administration of metoclopramide on blood levels of prolactin in the puerperium]
- …